For Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, Glenmark Pharmaceuticals receives ANDA approval.

0
514
WhatsApp D. Pharma Group Join Now
Telegram D. Pharma Group Join Now
Telegram Group Latest Pharma Jobs Join Now
Telegram B. Pharma Group Join Now
Telegram Medicine Update Group Join Now
WhatsApp B. Pharma/ GPAT Channel Join Now

Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the generic version of Compazine®1 Tablets, 5 mg and 10 mg, of GlaxoSmithKline, have been given final approval by the United States Food & Drug Administration (U.S. FDA). Glenmark Pharmaceuticals Ltd. (Glenmark) is an innovation-driven, international pharmaceuticals company. Glenmark Pharmaceuticals Inc., USA will market Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, in the United States.

During the twelve months ending in January 2023, sales of Compazine® Tablets, 5 mg and 10 mg were estimated by IQVIATM to have been $26.9 million*.

The current portfolio of Glenmark includes 46 ANDAs that are awaiting FDA approval and 182 medications that are currently approved for distribution in the US market. Glenmark continues to look for and investigate external development partnerships in addition to these internal filings to strengthen and hasten the expansion of its current pipeline and portfolio.

Download Pharmacy India Mobile App from Play store for the preparation of GPAT, NIPER, Pharmacist, DI and other Pharma Exams.

kn

LEAVE A REPLY

Please enter your comment!
Please enter your name here